adamax

a marketed nootropic name whose exact chemical identity is not established by a cited primary characterisation. scoped PubMed and ClinicalTrials.gov searches found no exact-compound record.

tier D · focus · none found in scoped exact-compound searches

verdict

Medsafe names Adamax as a marketed cognitive enhancer in an ACTH-analogue classification record, but that record does not establish its exact identity or effects. Exact PubMed and ClinicalTrials.gov searches found no Adamax-specific record, so efficacy, pharmacokinetics, and safety remain unknown.

why D-tier

D reflects a marketed cognitive claim with no exact efficacy result in the reviewed source set and an unresolved exact identity. The grade does not borrow evidence from Semax or P021.

the core tension

The marketed name is real enough to appear in New Zealand regulatory records, while the exact product identity and exact-compound evidence remain unresolved. Classification controls a medicine class; it does not prove a seller's structure, brain entry, efficacy, safety, or product approval.

what it is

Adamax is a marketed name. Medsafe names it while discussing ACTH analogues sold as cognitive enhancers, but the document does not provide an analytical characterisation of a product. A secondary listing and a chemical seller give incompatible descriptions. No cited primary source establishes the exact sequence, formula, molecular weight, residue count, CAS number, route, or finished form.

what it does

No Adamax-specific effect is established in the cited evidence. A chemical seller attributes brain, BDNF, TrkB, and endurance effects to the name, but supplies no Adamax study. Semax research and P021 research are separate parent-compound records. Neither establishes what a marketed Adamax product does.

origin

The development history is not established from the cited primary record. Medsafe documents that the name was marketed by 2025; it does not identify a developer, synthesis, or characterised product.

does it work

Unknown. On 2026-08-12, the cited exact PubMed query and exact ClinicalTrials.gov query returned no Adamax-specific record. Those scoped searches do not prove that no record can exist anywhere. They show that the reviewed source set provides no exact efficacy result to report.

key facts

• molecular formula: not established by a cited primary characterisation
• molecular weight: not established by a cited primary characterisation
• amino acids: unresolved because the exact chemical identity is not established
• half-life: unknown for Adamax
• type: marketed nootropic name with unresolved exact identity
• CAS: not established by a cited primary characterisation
• unresolved exact chemical identity
• none found exact record in the reviewed PubMed query
• none found exact record in the reviewed ClinicalTrials.gov query
• unknown route, form, PK, and safety

frequently asked questions

What is Adamax?

Adamax is a marketed nootropic name cited by Medsafe in an ACTH-analogue classification record. The cited record does not establish an exact chemical identity, and available secondary and seller listings disagree.

What does Adamax do?

Its effects are unknown. The reviewed exact-compound searches found no Adamax-specific study or registered trial, and seller claims cannot be replaced with Semax or P021 results.

Has Adamax been studied in people or animals?

The exact PubMed and ClinicalTrials.gov searches cited here returned no Adamax-specific record on 2026-08-12. This is a scoped search finding, not a claim about every database or unpublished record.

What are the side effects of Adamax?

Unknown. The cited exact-compound record provides no characterised exposure, pharmacokinetic, toxicology, or adverse-event evidence. Medsafe also warns that product quality is unknown in this imported novel-peptide market. Findings from Semax or P021 do not establish Adamax safety.

Is Adamax FDA approved?

No product named Adamax was located in the Drugs@FDA Products.txt dataset reviewed on 2026-08-12. In New Zealand, the ACTH-analogue class is classified as Prescription; that classification is not product approval.

What route or form has been established for Adamax?

None is established by the cited exact-compound record. Route, formulation, sequence, formula, and product identity remain unresolved.

related peptides

• semax: the named parent comparison; its findings do not establish Adamax effects

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.